Summary
Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albanese, J., Meterissian, S., Kontogiannea, M., Dubreuil, C., Hand, A., Sorba, S. & Dainiak, N. (1998). Biologically active Fas antigen and its cognate are expressed in plasma membrane-derived extracellular vesicles. Blood 91: 3862–3874.
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T. & Thompson, C. B. (1995). CD28 costimulation can promote T cell survival by enhancing the expression and Bcl-xL. Immunity 3: 87–98.
Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Bruer, M. J., Kiefer, M. C., Barr, P. J. & Mountz, J. D. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762.
Fellenberg, J., Mau, H., Schhuerpflung, C., Ewerbeck & Debatin, K. M. (1997). Modulation of resistance to anti-APO-1-induced apopotosis in osteosarcoma cells by cytokines. Int J Cancer 72: 536–542.
Hu, S., Vincenz, C., Ni, J., Gentz, R. & Dixit, V. M. (1997). I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 272: 17255–17257.
Japanese Urological, Association, Japanese Pathological, Society & Japanese Radiological, Society (1992). General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma. 2nd Edition, Aso Y. (ed) Kanehara-Shuppan: Tokyo
Jodo, S., Kobayashi, S., Kayagaki, N., Ogura, Y., Feng, Y., Amasaki, Y., Fujisaku, A., Azuma, M., Yagita, H., Okumura, K. & Koike, T. (1997). Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107: 89–95.
Knipping, E., Debatin, K-M, Stricker, K., Heilig, B., Eder, A. & Krammer, P. H. (1995). Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T- cell leukemias. Blood 85: 1562–1569.
Lanigan, D. (1995). Prognostic factors in renal cell carcinoma. Br J Urol 75: 565–571.
Midis, G. P., Shen, Y. & Owen-Schaub, L. B. (1996). Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56: 3870–3874.
Nagata, S. (1994). Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57: 129–144.
Nonomura, N., Miki, T., Yokoyama, M., Imazuy, T., Takeda, T., Takeuchi, S., Kanno, N., Nishimura, K., Kojima, Y. & Okuyama, A. (1996). Fas/APO-1-mediated apoptosis of human renal cell cancer. Biochem Biophys Res Com 229: 945–951.
Owen-Schaub, L. B., Angelo, L. S., Radinsky, R., Warew, C. F., Gesner, T. G. & Bartos, D. P. (1995). Soluble Fas/Apo-1 in tumor cells: a potential regulator of apoptosis?. Cancer Lett 94: 1–8.
Tomita, Y., Kawasaki, T., Bilim, V., Takeda, M. & Takahashi, K. (1996a). Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer 68: 132–135.
Tomita, Y., Bilim, V., Kawasaki, T., Takeda, M., Takahashi, K., Ismail, O., Magnusson, K. & Wiman, K. (1996b). Frequent expression of bcl-2 in renal-cell carcinomas carring wild-type p53. Int J Cancer 66: 322–325.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kimura, M., Tomita, Y., Imai, T. et al. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients. Br J Cancer 80, 1648–1651 (1999). https://doi.org/10.1038/sj.bjc.6690576
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690576
Keywords
This article is cited by
-
Tumor cell secretion of soluble factor(s) for specific immunosuppression
Scientific Reports (2015)
-
Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma
British Journal of Cancer (2006)